Patents by Inventor Volker Wacheck

Volker Wacheck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CANCER
    Publication number: 20180228795
    Abstract: The present invention provides a method of treating squamous histology cancers, breast cancer, prostate cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, and colorectal cancer in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof; in combination with an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 8, 2016
    Publication date: August 16, 2018
    Inventors: Richard Paul Beckmann, Gregory Paul Donoho, Aimee Karis Lin, Volker Wacheck
  • COMBINATION THERAPY FOR CANCER
    Publication number: 20180104234
    Abstract: The present invention provides a method of treating squamous histology cancers and PI3K pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of necitumumab.
    Type: Application
    Filed: May 4, 2016
    Publication date: April 19, 2018
    Inventors: Gregory Paul Donoho, Volker Wacheck
  • ANTI-MET IN COMBINATION WITH ANTI-VEGFR2 ANTIBODIES THERAPY FOR CANCER
    Publication number: 20160369004
    Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating cancer selected from the group consisting of gastric cancer, HCC, and RCC comprising a C8-H241 Ab, preferably, C8-H241-IgG4, more preferably, emibetuzumab, in combination, as described herein, with an anti-VEGFR2 Ab, preferably, ramucirumab.
    Type: Application
    Filed: February 25, 2015
    Publication date: December 22, 2016
    Applicant: Eli Lilly and Company
    Inventors: Bronislaw Pytowski, Jonathan David Schwartz, Volker Wacheck, Sau-Chi Betty Yan